HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 11 July 2016

NICE approves first drug from old Cancer Drugs Fund

But it’s not going to be in the new CDF?  It’s not clear, but the re-appraisal has a new section “Cancer Drugs Fund reconsideration” that seems to say that further data collection is not possible.  However, with one ‘plausible’ estimate of post-treatment benefits and another ‘no unreasonable’ estimate of best supportive care costs, it becomes cost-effective after a further discount from Pfizer.

Read it yourself and see what you think.  It’s here.